User login
Dr David Henry’s October podcast for The Journal of Community and Supportive Oncology, begins with a discussion of the recent approval of panobinostat for the treatment of relapsed and refractory multiple myeloma and of dinutuximab combination therapy as a first-line option for high-risk neuroblastoma in children. He also highlights two Review articles, one on cancer-related pain management, and another on current practice with endocrine therapy in metastatic breast cancer, both of which provide the reader with detailed, up-to-date overviews of current literature on the topics and clinical practice. Two Original Reports examine drugs costs and outcomes as they pertain to the practicing oncologist. The first article looks at the value of anticancer drugs in metastatic castrate-resistant prostate cancer; the second examines the implications of hospitalizations of 5 or more days on outcomes among patients with head and neck cancer who have received radiotherapy. Dr Henry rounds off his podcast with Case Reports on zoledronic acid-induced hypocalcemia in hyercalcemia of malignancy and neuroendocrine carcinaoma of the larynx with metastasis to the eyelid.
Click on the download icon at the top of this introduction to listen to the podcast.
Dr David Henry’s October podcast for The Journal of Community and Supportive Oncology, begins with a discussion of the recent approval of panobinostat for the treatment of relapsed and refractory multiple myeloma and of dinutuximab combination therapy as a first-line option for high-risk neuroblastoma in children. He also highlights two Review articles, one on cancer-related pain management, and another on current practice with endocrine therapy in metastatic breast cancer, both of which provide the reader with detailed, up-to-date overviews of current literature on the topics and clinical practice. Two Original Reports examine drugs costs and outcomes as they pertain to the practicing oncologist. The first article looks at the value of anticancer drugs in metastatic castrate-resistant prostate cancer; the second examines the implications of hospitalizations of 5 or more days on outcomes among patients with head and neck cancer who have received radiotherapy. Dr Henry rounds off his podcast with Case Reports on zoledronic acid-induced hypocalcemia in hyercalcemia of malignancy and neuroendocrine carcinaoma of the larynx with metastasis to the eyelid.
Click on the download icon at the top of this introduction to listen to the podcast.
Dr David Henry’s October podcast for The Journal of Community and Supportive Oncology, begins with a discussion of the recent approval of panobinostat for the treatment of relapsed and refractory multiple myeloma and of dinutuximab combination therapy as a first-line option for high-risk neuroblastoma in children. He also highlights two Review articles, one on cancer-related pain management, and another on current practice with endocrine therapy in metastatic breast cancer, both of which provide the reader with detailed, up-to-date overviews of current literature on the topics and clinical practice. Two Original Reports examine drugs costs and outcomes as they pertain to the practicing oncologist. The first article looks at the value of anticancer drugs in metastatic castrate-resistant prostate cancer; the second examines the implications of hospitalizations of 5 or more days on outcomes among patients with head and neck cancer who have received radiotherapy. Dr Henry rounds off his podcast with Case Reports on zoledronic acid-induced hypocalcemia in hyercalcemia of malignancy and neuroendocrine carcinaoma of the larynx with metastasis to the eyelid.
Click on the download icon at the top of this introduction to listen to the podcast.